Updated Preliminary Data from SMA FIREFISH Program in Type 1 Babies with Risdiplam

risdiplam- RG7916 is well tolerated at all dose levels with no drug-related safety findings – SOUTH PLAINFIELD, N.J., June 16, 2018 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of updated interim clinical data from Part 1 of the FIREFISH study investigating risdiplam (RG7916) in babies with… Att fortsätt läsa